India's weight-loss drug boom: Novo Nordisk talks about GLP-1 generics after patent expiry
Corroborated by 1 source from 1 publisher
asiahealth1d ago
TL;DR
According to cnbc.com, watch now India's weight-loss drug boom: Novo Nordisk talks about GLP-1 generics after patent expiry The patent on semaglutide, found in Novo Nordisk's Ozempic and Wegovy weight-loss drugs, expired in India on March 20.